Product Description
Broncho-Vaxom is effective and safe for the treatment of acute episodes of respiratory tract infections and for preventing recurrences.
Mechanisms of Action: Immunostimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Belgium | Brazil | Bulgaria | Chile | Czech | Egypt | Germany | Greece | Hungary | Indonesia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Switzerland | Turkey | Ukraine | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: OM Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Germany, Hungary, Poland, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic|Other|Respiratory Sounds
Phase 1: Asthma, Allergic|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BV-2020/09 | P2 |
Recruiting |
Respiratory Sounds |
2026-09-30 |
12% |
2025-04-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| BV-2020/09 | P2 |
Recruiting |
Other |
2026-02-28 |
12% |
2025-05-02 |
Treatments |
| BV-2022/11 | P1 |
Completed |
Asthma, Allergic |
2025-02-19 |
23% |
2025-03-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| 2021-003179-33 | P2 |
Active, not recruiting |
Dermatitis, Atopic |
2024-03-29 |
2022-03-13 |
Treatments |
|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |